CytoSwitch is a small biotech developer based at the LMU Munich which is developing an innovative technology to fight cancer tumours. It is currently taking its lead drug candidate to preclinical testing in mouse models. In parallel, CytoSwitch is also developing research reagents for the biotech and academic markets. Currently in the pre-seed stage, it is carrying out pre-clinical studies for the next three years (2017-2020) through the EXIST German government funding programme.
Company Details
- Address
- Dept. Of Pharmacy, Butenandtstrasse 5-13, Munich,bavaria 81377,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cytoswitch.com
- HQ
- Munich, Bavaria
Cytoswitch Questions
Cytoswitch's website is cytoswitch.com
Cytoswitch's LinkedIn profile is https://de.linkedin.com/company/cytoswitch
Cytoswitch's industry is
Biotechnology Research
Cytoswitch's top competitors are
Fobs Beteiligungsgesellschaft,
Nu Emotions Gmbh,
Thouet Ventures,
Landhaus Himmelpfort Am See,
Green.health,
Entire Senses,
Cstream,
Amsilk Gmbh | Biogenius Materials,
Nuard Ventures,
Htgf | High-Tech Gründerfonds.
Cytoswitch's categories are Biotechnology Research
